11th Jan 2016 08:18
LONDON (Alliance News) - Immunotherapies developer Scancell Holdings PLC on Monday said it has received data showing patient immunologic response to its SCIB1 cancer vaccine.
The response from the patients can be demonstrated through monitoring changes to the diversity of T cells found in the blood, the company said.
"These results provide further evidence that SCIB1 can induce T cell responses that are associated with disease control," said Lindy Durrant, the joint-chief executive of Scancell.
Scancell shares were up 7.0% early Monday to 23.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Scancell Holdings